Hemas Holdings PLC: An Investment Perspective

Executive Summary: Hemas Holdings PLC (HHL) operates as a diversified conglomerate in Sri Lanka, with significant presence in Consumer Brands, Healthcare, and Mobility sectors. The current trading price of its stock on the Colombo Stock Exchange (CSE) is LKR24.5. A 12-month target price of LKR32.8 has been suggested, indicating a potential total return of 37.5%, which includes a forward dividend yield of 3.8%. Based on an initial assessment of the available information, which points towards strong fundamentals, strategic growth initiatives, and positive analyst sentiment, a preliminary investment recommendation leans towards a **Buy**, subject to the comprehensive analysis presented in this report.

Company Profile and Recent Highlights: Hemas Holdings PLC stands as a well-established conglomerate in Sri Lanka, demonstrating a focused interest across the Consumer Brands, Healthcare, and Mobility sectors.[1] The company's shares are publicly traded on the Colombo Stock Exchange under the ticker symbol HHL.N0000.[3] With a history spanning 75 years, Hemas has built a strong foundation in the Sri Lankan market and has also expanded its operations into Bangladesh.[2] This long operational history suggests a deep understanding of the market dynamics and a level of resilience that can be attractive to investors.[6] The company's diversification across multiple sectors provides a degree of insulation against downturns specific to any single industry, although it necessitates proficient management across these varied business areas.

Recent developments at Hemas include a significant leadership change with the appointment of Ashish Chandra as the Group Chief Executive Officer (CEO) in May 2025.[7] Chandra brings over 27 years of experience in emerging markets, coupled with a focus on customer-centric innovation and a digital-first approach.[7] His previous role as CEO and Managing Director of Airtel Sri Lanka, where he orchestrated a landmark industry merger, highlights his strategic acumen and experience in scaling businesses.[7] This appointment marks a strategic inflection point for Hemas, signaling a sharpened focus on accelerating growth within larger emerging markets, expanding into adjacent sectors, and driving a technology-led transformation to ensure sustained success.[7] A new CEO with a strong background in relevant areas such as emerging markets and technology could serve as a catalyst for future growth and strategic realignments within the company. Investors should closely monitor subsequent company announcements and performance under this new leadership.

In other key news, Fitch Ratings affirmed Hemas Holdings at 'AAA(lka)' with a 'Stable Outlook' in April 2025.[9] This rating underscores the company's defensive operating cash flows, primarily driven by its healthcare and consumer brands businesses, which contribute approximately 90 percent of the group's EBIT.[9] Fitch also anticipates that Hemas will maintain a robust balance sheet as it explores significant investments in its core businesses over the next few years.[9] The company reported strong performance in earnings growth for the nine months ended December 31, 2024.[6] Furthermore, Hemas is actively exploring investment opportunities in Kenya, with a focus on establishing specialized hospitals, laboratories, and pharmaceutical ventures.[10] Finally, a sub-division of shares was announced by the company in March 2025.[12] The 'AAA' rating from Fitch provides a strong indication of the company's financial stability and low credit risk, which is a positive signal for long-term investors. The planned increase in capital expenditure suggests a commitment to future growth, particularly within the healthcare sector, aligning directly with the user's query. The returns generated from these investments will be critical to observe in the coming years. The exploration of the Kenyan market represents a notable step in Hemas' internationalization strategy within the healthcare domain, although it also introduces new market-specific risks and opportunities. While a share sub-division can sometimes enhance stock liquidity and accessibility for smaller investors, it does not inherently alter the fundamental value of the company.

Financial Performance and Stability Assessment: The affirmation of Hemas Holdings' 'AAA(lka)' rating with a 'Stable Outlook' by Fitch Ratings speaks volumes about the company's financial robustness.[9] This rating is underpinned by the defensive nature of its healthcare and consumer sectors, which consistently generate strong operating cash flows.[9] Fitch highlights Hemas' leading position in pharmaceutical import and distribution, a benefit stemming from reduced competition following import challenges in recent years that disproportionately affected smaller players.[9] The company's well-established local distribution network and enduring global partnerships are also key advantages contributing to this strong rating.[9] Demand for Hemas' pharmaceutical manufacturing and hospital operations is also on the rise, fueled by an aging population.[9] Fitch expects Hemas to maintain its leading position in the home and personal care segment and its market leadership in stationery products, sustaining market share through continuous innovation and varied packaging options tailored to consumer purchasing power.[9] The stability in healthcare revenue is anticipated due to the essential nature of pharmaceutical imports and the consistent demand for healthcare services.[13] Fitch expects Hemas to continue its distribution operations, even amidst economic challenges, and to effectively manage margin pressures arising from currency devaluation through contractual arrangements, cost efficiencies, and price revisions.[13] Importantly, Fitch anticipates that Hemas will adopt a prudent approach to its planned and potential opportunistic investments, consistent with its established track record.[9]

To gain a deeper understanding of Hemas Holdings PLC's financial health, an examination of its key performance indicators over recent years is crucial.

As at 31 March (LKR)	FY 24	FY 23	FY 22	FY 21	FY 20
Revenue (Bn)	121.6	113.9	78.8	64.5	60.0
Net Profit (Bn)	6.1	4.3	4.3	3.3	1.2
Earnings per share (Rs.)	10.24	7.16	7.10	5.50	2.10
Dividend per share (Rs.)	2.35	2.35	4.40	0.40	1.50
Net Asset Value per share	72.8	64.4	59.2	53.5	46.8
Market Capitalization (Bn)	48.0	38.8	23.8	49.8	33.5
Price to Earnings Ratio	7.9	9.1	6.5	15.2	27.1
ROE (%)	15.3	13.4	13.8	10.3	4.4
ROCE (%)	22.1	22.9	17.2	15.7	9.6

Source: Hemas Holdings PLC Investor Relations [6]

The table above highlights a positive trend in several key metrics. Revenue has shown consistent growth over the past five fiscal years, culminating in LKR 121.6 billion in FY24.[6] Net profit also experienced a significant increase in FY24, reaching LKR 6.1 billion, indicating improved profitability.[6] This growth is further reflected in the Earnings per Share (EPS), which rose to LKR 10.24 in FY24.[6] While the Dividend per Share (DPS) saw some fluctuation, it has remained relatively stable in the last two years.[6] The increase in Return on Equity (ROE) and Return on Capital Employed (ROCE) in FY24 suggests enhanced profitability and efficiency in the utilization of shareholder equity and invested capital.[6] Notably, the Price to Earnings (P/E) ratio decreased in FY24, potentially indicating a more attractive valuation relative to the company's earnings.[6]

Recent earnings reports further underscore this positive financial trajectory. Hemas announced strong earnings growth for the nine months ended December 31, 2024.[6] The performance in Q3 FY25 was particularly noteworthy, with a 36.3 percent year-on-year growth in consolidated earnings, reaching LKR 3.0 billion.[15] Revenue also increased by 6.4 percent to LKR 33.2 billion, and operating profit saw a substantial rise of 25.7 percent to LKR 4.9 billion.[15] This revenue growth was evident across all sectors, as the Group's businesses effectively leveraged efficiency improvements and enhanced competitiveness amidst a cautiously improving consumer confidence.[15] A significant factor contributing to this performance was the substantial decrease of 47.4 percent in the net finance expenses of the Group, which fell to LKR 271.2 million. This reduction was primarily due to lower interest rates and the successful reduction of net debt resulting from improved cash flows.[15] The consistent pattern of earnings growth signals a positive and upward trend in the company's financial performance. The successful reduction of net debt and the corresponding decrease in finance expenses are positive indicators of improved financial health and prudent cash flow management. Moreover, the fact that revenue growth was achieved across all operating sectors in Q3 FY25 highlights a broad-based strength and resilience in the company's overall operations.

Growth Opportunities in Healthcare: The healthcare sector presents significant growth avenues for Hemas Holdings PLC, driven by strategic expansions and a focus on essential medical services. Plans are well underway for a substantial expansion of Hemas Thalawathugoda Hospital, with the bed capacity slated to increase from 70 to 150.[17] This expansion is anticipated to require a significant investment, estimated to be at least LKR 6 to 7 billion.[17] The primary driver behind this expansion is the high demand for quality healthcare services in the Thalawathugoda area, a bustling residential and industrial town.[21] To cater to a broader range of medical needs, Hemas also intends to introduce new specialized services at the expanded facility, including cardiology, oncology, and neurology.[17] The existing Hemas Thalawathugoda Hospital already offers a wide array of medical services, including emergency care, pediatric care, surgeries, and cardiology, supported by well-stocked pharmacies and state-of-the-art laboratories.[21] The significant investment and planned increase in bed capacity at Hemas Thalawathugoda Hospital strongly indicate the company's confidence in the growth potential of the healthcare sector within Sri Lanka. The substantial capital commitment suggests a long-term strategic focus on this segment. Furthermore, the introduction of specialized services like cardiology, oncology, and neurology will not only broaden the hospital's service offerings but also tap into additional revenue streams. The hospital's existing infrastructure and its achievement of international accreditations, such as the Australian Council of Healthcare Standards International (ACHSI), provide a robust foundation for this ambitious expansion.[23]

Beyond domestic expansion, Hemas is actively exploring investment opportunities within the healthcare sector in East Africa, with a particular focus on Kenya.[10] The company's delegation has engaged in discussions with Kenyan health authorities in Nairobi to explore the potential for establishing specialized hospitals, laboratories, and pharmaceutical ventures.[10] These discussions have emphasized the importance of patient-centric care and innovation, principles that are central to Hemas Hospital's established reputation.[10] The East African healthcare market presents a promising growth landscape, driven by increasing population, a rising burden of non-communicable diseases, and a growing demand for quality healthcare services.[29] However, this expansion also introduces new challenges related to navigating different regulatory environments and increased competition within the region. The strategic focus on specialized hospitals, laboratories, and pharmaceuticals in Kenya aligns well with Hemas' existing expertise and strengths within the healthcare industry.

A crucial component of Hemas' healthcare strategy is the role of Morison, which emphasizes the manufacturing and distribution of high-margin, essential medications at affordable prices within Sri Lanka.[34] Morison recently launched new cardiovascular drugs, including Cilnidipine and Rivaroxaban, at significantly lower prices compared to existing market rates, demonstrating its commitment to making premium healthcare affordable.[39] Furthermore, Morison has partnered with the Sri Lanka College of Endocrinologists to launch a certificate training program for primary healthcare professionals in diabetes care, aiming to enhance the quality of diabetes management across the country.[34] Morison operates a state-of-the-art pharmaceutical manufacturing facility in Homagama, which is compliant with European Union Good Manufacturing Practices (EU GMP) standards, signifying a commitment to high-quality production.[34] Morison's strategic focus on essential medications coupled with its commitment to affordable pricing directly addresses the healthcare needs of the Sri Lankan population and provides a stable and reliable revenue stream for Hemas. The EU GMP compliance of Morison's manufacturing facility not only ensures high standards but also opens up potential opportunities for exporting pharmaceutical products in the future. The collaborative partnerships for training healthcare professionals not only enhance Morison's reputation within the industry but also contribute to the overall strengthening of the healthcare ecosystem in Sri Lanka.

Strength of Consumer Brands and Education Sectors: Hemas Holdings PLC maintains a strong foothold in both the Consumer Brands and Education sectors within Sri Lanka. Its Consumer Brands segment holds a leading position in the country's Fast-Moving Consumer Goods (FMCG) space.[9] This market leadership is driven by a consistent focus on innovation and the benefits of rising disposable income within the Sri Lankan economy. Hemas has demonstrated a commitment to introducing new products and refreshing existing ones to cater to evolving consumer preferences. Recent examples include the launch of Vivya sunscreen and Vitamin C range, as well as the Velvet body wash Naturals range.[15] Additionally, Baby Cheramy introduced a liquid soap, and Goya Soap launched new variants, further expanding the product offerings.[49] Despite economic challenges and shifts in consumer buying patterns towards value-for-money options, Hemas has successfully maintained market shares across most categories by introducing lower grammage products and value packs.[15] This continuous innovation and adaptation to consumer needs are vital for sustaining market leadership in the highly competitive FMCG sector. The strategic focus on catering to both the premium and value-conscious segments of the market enables Hemas to address a wide spectrum of consumer demands and purchasing capabilities.

In the Education sector, Hemas' brand Atlas remains the dominant player in Sri Lanka.[9] Atlas has consistently focused on product development and market expansion to maintain its leadership position. The brand has also undertaken various initiatives to reinforce its commitment to education, such as the 'Light a Future' donation drive initiated by Atlas [52] and the ongoing SipSavi Scholarship Program, which provides financial support to deserving children.[48] Furthermore, Atlas is expanding its reach beyond traditional stationery by venturing into non-stationery school-related categories, indicating a strategic move to capture a larger share of the education market.[51] The strong brand recognition that Atlas enjoys, coupled with its engagement in social responsibility initiatives, contributes significantly to its enduring dominance in the education sector. By expanding its product portfolio to include non-stationery items, Atlas is strategically broadening its market presence and creating additional revenue opportunities within the education landscape.

International Market Performance: Hemas Holdings PLC has a presence in the international market, with Bangladesh being a key region of operation. The query mentions a recovery in Bangladesh supporting international growth. While Hemas has faced challenges in Bangladesh due to rising inflation and increased price sensitivity, which has led some consumers to opt for more affordable alternatives, the company has implemented strategies to maintain its market position.[15] For instance, 'Kumarika', a flagship Value-Added Hair Oil (VAHO) product, has successfully maintained its market share despite these challenges.[15] Hemas has also introduced value-for-money products and leveraged its extensive retail distribution footprint in Bangladesh, which expanded from 114,000 to 132,000 outlets.[52] The ability of Hemas to achieve a recovery in its Bangladesh operations, even amidst persistent economic headwinds, underscores the resilience and adaptability of its international business segment. The strategy of tailoring product offerings and pricing to align with the specific economic conditions and consumer preferences in Bangladesh is crucial for ensuring sustained growth in this important international market.

Stock Valuation and Investment Recommendation: The user query points to a 12-month target price of LKR32.8 for Hemas Holdings PLC, which, when compared to the current trading price of LKR24.5, suggests a substantial potential total return of 37.5%. This return includes a forward dividend yield of 3.8%. Such a significant potential upside makes HHL an appealing investment prospect, provided that a thorough analysis supports this valuation.

Examining analyst perspectives from the research material reveals a generally positive outlook on Hemas Holdings PLC, with target prices often exceeding the current trading price. Bartleet Religare issued a BUY recommendation with a target price of LKR 134.00.[55] First Capital maintained a BUY rating with fair value estimates of LKR 95.0 for FY25E and LKR 115.0 for FY26E.[56] Simply Wall St. reported price target increases to LKR 119.[58] These analyst targets are considerably higher than the current market price, potentially indicating an undervaluation of the stock. However, it's important to note the variation in these targets, which could reflect different analytical approaches, timeframes, or market assumptions.

Current stock price information from various sources shows some discrepancies and varying dates. As of March 18, 2025, the price was noted as LKR 117.25.[3] Investing.com provided a price of LKR 78.80 as of September 30, 2024.[4] The Colombo Stock Exchange quoted a range of LKR 24.40 - 24.80.[5] Finbox.com reported a price of LKR

24.35 as of the latest data.[59] Simply Wall St. indicated a current share price of LKR 24.50.[60] TradingView showed a price of 24.5 LKR.[61] This inconsistency highlights the importance of using real-time data from a reliable source when making investment decisions.

Key stock statistics provide further context. The Price to Earnings (P/E) ratio for Hemas Holdings PLC is around 10.15-10.43 [3], which appears reasonable in the context of the company's growth prospects and financial stability. The annual dividend yield is approximately 3.33% to 3.8% [3], offering an additional return for investors. The market capitalization is around LKR 71.68 billion.[3]

Analyst/Source	Target Price (LKR)	Date	Recommendation
Bartleet Religare	134.00	3Q FY25	BUY
First Capital	95.00 (FY25E)	Nov 2024	BUY
First Capital	115.00 (FY26E)	Nov 2024	BUY
Simply Wall St.	119.00	Mar 2025	N/A
User Query (Implied)	32.80	12-Month	N/A

Note: FY25E and FY26E refer to Fiscal Year 2025 Estimate and Fiscal Year 2026 Estimate, respectively.

The analyst target prices, while varied, generally suggest a significant potential upside from the current trading price. This indicates that the market may not fully be reflecting the intrinsic value or future growth prospects of Hemas Holdings PLC.

Key Risks and Considerations: Investing in Hemas Holdings PLC, like any stock, involves certain risks and considerations. Macroeconomic factors in Sri Lanka remain a key influence on the company's performance. While the economic situation is showing signs of improvement with declining inflation and stable exchange rates, potential instability, currency fluctuations, and changes in government policies could impact Hemas' operations and profitability.[15] The regulatory environment, particularly within the healthcare sector, could pose challenges. Delays or changes in regulations related to pharmaceutical manufacturing, hospital expansions, or pricing could affect the company's growth plans.[49] The FMCG and healthcare markets in Sri Lanka are competitive, with both local and international players vying for market share. Additionally, Hemas' expansion into Bangladesh and its potential entry into East Africa expose it to increased competition in those regions. Integrating new acquisitions or successfully establishing operations in new markets like Kenya carries inherent risks related to cultural differences, regulatory compliance, and operational challenges. A global economic slowdown could also impact consumer spending, potentially affecting the demand for Hemas' consumer products and the performance of its international operations.

Conclusion: Hemas Holdings PLC presents a compelling investment opportunity based on its strong market position across diverse sectors, promising growth prospects in healthcare and international markets, and a stable financial performance. The company's 'AAA(lka)' rating from Fitch underscores its financial strength and resilience. The planned expansion of Hemas Thalawathugoda Hospital and the exploration of the East African healthcare market signal a commitment to future growth in a defensive sector. Morison's focus on affordable essential medications further strengthens the healthcare segment. The continued market leadership of Consumer Brands and Atlas in their respective sectors provides a stable revenue base. While operations in Bangladesh have faced challenges, the signs of recovery are encouraging for international growth. Analyst perspectives generally indicate a significant potential upside in the stock price, with target prices substantially above the current trading level.

However, investors should be mindful of the risks associated with macroeconomic conditions in Sri Lanka, the regulatory environment, competitive pressures, and the challenges of international expansion. Careful monitoring of these factors, along with the company's financial results and progress on its strategic initiatives, is essential.

Considering the current trading price of LKR24.5, the potential for significant returns based on analyst target prices, the company's strong fundamentals, and its strategic growth initiatives, the investment recommendation for Hemas Holdings PLC is a **Buy**. Investors should conduct their own due diligence and consider their individual risk tolerance before making an investment decision. It is advisable to monitor the company's quarterly financial results, progress on the Thalawathugoda Hospital expansion and East African ventures, and any further analyst reports to stay informed about the investment.

Works cited

1. Hemas Holdings - Wikipedia, accessed May 19, 2025,

https://en.wikipedia.org/wiki/Hemas_Holdings
2. Hemas Holdings PLC I Annual Report 2023/24, accessed May 19, 2025, https://hemas.com/assets/downloads/financial-reports/annual-report-2023-2024.pdf
3. Hemas Holdings PLC, HHL.N0000:CSE summary - FT.com - Markets data - Financial Times, accessed May 19, 2025, https://markets.ft.com/data/equities/tearsheet/summary?s=HHL.N0000:CSE
4. Hemas Holdings PLC Stock Price Today | CM: HHL Live - Investing.com, accessed May 19, 2025, https://www.investing.com/equities/hemas-holdings
5. hemas holdings plc - CSE - Colombo Stock Exchange, accessed May 19, 2025, https://www.cse.lk/pages/company-profile/company-profile.component.html?symbol=HHL.N0000
6. Investors - Hemas, accessed May 19, 2025, https://hemas.com/investor.html
7. Hemas Holdings PLC Appoints Ashish Chandra as Group Chief Executive Officer, accessed May 19, 2025, https://lankatalks.com/post/hemas-holdings-plc-appoints-ashish-chandra-as-group-chief-executive-officer
8. Colombo Stock Exchange: CSE, accessed May 19, 2025, https://www.cse.lk/
9. Fitch affirms Hemas Holdings at 'AAA(lka)'; Outlook Stable - Business News | Daily Mirror, accessed May 19, 2025, https://www.dailymirror.lk/business-news/Fitch-affirms-Hemas-Holdings-at-AAAlka-Outlook-Stable/273-307610
10. Hemas explores investment opportunities in Kenya - The Island, accessed May 19, 2025, https://island.lk/hemas-explores-investment-opportunities-in-kenya/
11. Hemas Group Sri Lanka sets sights on Africa - Business News | Daily Mirror, accessed May 19, 2025, https://www.dailymirror.lk/business-news/Hemas-Group-Sri-Lanka-sets-sights-on-Africa/273-267316
12. CSE - Colombo Stock Exchange, accessed May 19, 2025, https://www.cse.lk/#19836
13. Hemas Holdings PLC - Fitch Group, accessed May 19, 2025, https://your.fitch.group/rs/732-CKH-767/images/fitch-hemas-holdings_fitch_10127264.pdf
14. Hemas Holdings PLC: Profitability and Financial Performance for year ended 31st March 2024 - LankaBIZ, accessed May 19, 2025, https://lankabizz.net/2024/05/23/hemas-holdings-plc-profitability-and-financial-performance-for-year-ended-31st-march-2024/
15. Hemas Holdings PLC I Interim Report 2024/25 Q3, accessed May 19, 2025, https://hemas.com/assets/downloads/quarterly-reports/quarterly-report-2024-2025-q3.pdf
16. Q3 Presentations - Hemas Holdings PLC, accessed May 19, 2025, https://hemas.com/assets/downloads/investor-presentations/investor-presentations-2024-2025-q3.pdf
17. Hemas Hospitals announces expansion strategy with focus on acquisitions - Business News, accessed May 19, 2025,

https://www.dailymirror.lk/business-news/Hemas-Hospitals-announces-expansion-strategy-with-focus-on-acquisitions/273-270741
18. Celebrating 15 years in healthcare Hemas signals bid for Lanka Hospitals - Daily FT, accessed May 19, 2025, https://www.ft.lk/front-page/Celebrating-15-years-in-healthcare-Hemas-signals-bid-for-Lanka-Hospitals/44-754943
19. Rising Cost, Brain-Drain Challenge Hemas Hospitals - Ceylon Today, accessed May 19, 2025, https://ceylontoday.lk/2023/11/08/rising-cost-brain-drain-challenge-hemas-hospitals/
20. Hemas Hospitals planning to link-up with top Singaporean hospitals and universities, accessed May 19, 2025, https://island.lk/hemas-hospitals-planning-to-link-up-with-top-singaporean-hospitals-and-universities/
21. Presidential opening for Hemas' Rs. 1.3 b hospital in Thalawathugoda | Daily FT, accessed May 19, 2025, https://www.ft.lk/article/157780/Presidential-opening-for-Hemas---Rs--1-3-b-hospital-in-Thalawathugoda
22. Hemas Hospital opens new facility in Sri Lanka - DesignCurial - FX Design, accessed May 19, 2025, https://www.designcurial.com/news/hemas-hospital-opens-new-facility-in-sri-lanka/
23. Hemas Hospital Thalawathugoda marks 5 years of unwavering commitment to the best in healthcare - Adaderana Biz English | Sri Lanka Business News, accessed May 19, 2025, https://bizenglish.adaderana.lk/hemas-hospital-thalawathugoda-marks-5-years-of-unwavering-commitment-to-the-best-in-healthcare/
24. Hemas Hospital Thalawathugoda now with full international accreditation - Adaderana Biz English | Sri Lanka Business News, accessed May 19, 2025, https://bizenglish.adaderana.lk/hemas-hospital-thalawathugoda-now-with-full-international-accreditation/
25. Hemas Hospital, Thalawathugoda - EDB Sri Lanka - Export Development Board, accessed May 19, 2025, https://www.srilankabusiness.com/exporters-directory/company-profiles/hemas-hospital-thalawathugoda/
26. Hemas Hospitals - Wikipedia, accessed May 19, 2025, https://en.wikipedia.org/wiki/Hemas_Hospitals
27. Hemas hospital Thalawathugoda now offers affordable and convenient 'day surgery packages' for a wide range of surgeries - Adaderana Biz English | Sri Lanka Business News, accessed May 19, 2025, https://bizenglish.adaderana.lk/hemas-hospital-thalawathugoda-now-offers-affordable-and-convenient-day-surgery-packages-for-a-wide-range-of-surgeries/
28. Hemas Thalawathugoda - Hospitals, accessed May 19, 2025, https://hemashospitals.com/en/hospitals/thalawathugoda/
29. TechEmerge Health East Africa, accessed May 19, 2025,

https://techemerge.org/initiatives/techemerge-health-east-africa/
30. Healthcare Innovation in East Africa: Navigating the Ecosystem – CASE at Duke, accessed May 19, 2025, https://centers.fuqua.duke.edu/case/knowledge_items/healthcare-innovation-in-east-africa-navigating-the-ecosystem/
31. Healthcare Innovation in East Africa, accessed May 19, 2025, https://www.innovationsinhealthcare.org/East%20Africa%20Landscape%20Report%20-%20SEAD.pdf
32. Identifying Key Challenges Facing Healthcare Systems In Africa And Potential Solutions, accessed May 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6844097/
33. Healthcare - Kenya Investment Authority (KenInvest), accessed May 19, 2025, https://www.investkenya.go.ke/sector/healthcare/
34. The Sri Lanka College of Endocrinologists Partners with Morison to Address the Rising Challenge of Diabetes - Hemas | News, accessed May 19, 2025, https://hemas.com/news/the-sri-lanka-college-of-endocrinologists-partners-with-morison-to-address-the-rising-challenge-of-diabetes.html
35. The Sri Lanka College of Endocrinologists in partnership with Morison, marks a key milestone in the fight against diabetes in Sri Lanka - Mawratanews.lk, accessed May 19, 2025, https://mawratanews.lk/business/the-sri-lanka-college-of-endocrinologists-in-partnership-with-morison-marks-a-key-milestone-in-the-fight-against-diabetes-in-sri-lanka/
36. Morison launches its exclusive CSR platform 'Suwa Deya', reaffirming its purpose of 'Making Premium Healthcare Affordable' - Hemas, accessed May 19, 2025, https://hemas.com/news/morison-launches-its-exclusive-csr-platform-suwa-deya.html
37. Morison gearing to re-shape pharmaceutical industry in SL by 2030 - The Island, accessed May 19, 2025, https://island.lk/morison-gearing-to-re-shape-pharmaceutical-industry-in-sl-by-2030/
38. Our Journey Upstream: On the Road to Making Premium Healthcare Affordable - MORISON, accessed May 19, 2025, https://www.morison.lk/our-journey-upstream-on-the-road-to-making-premium-healthcare-affordable/
39. News Archives - Morison Limited, accessed May 19, 2025, https://www.morison.lk/category/news/
40. Adding value to SRI LANKA's ever-evolving healthcare landscape: Hemas Healthcare - Features | Daily Mirror, accessed May 19, 2025, https://www.dailymirror.lk/features/Adding-value-to-SRI-LANKAs-ever-evolving-healthcare-landscape-Hemas-Healthcare/185-287018
41. Morison launches its exclusive CSR platform â€˜Suwa Deyaâ€™, reaffirming its purpose of â€˜Making Premium Healthcare Affordableâ€™ - Eyeview Sri Lanka, accessed May 19, 2025, https://eyeviewsl.com/morison-launches-its-exclusive-csr-platform-suwa-deya-r

eaffirming-its-purpose-of-making-premium-healthcare-affordable/
42. Morison Enters the Cardiovascular Space by 'Touching More Hearts', accessed May 19, 2025, https://www.lankabusinessnews.com/morison-enters-the-cardiovascular-space-by-touching-more-hearts/
43. Morison opens largest pharma manufacturing facility in Sri Lanka - Daily Mirror, accessed May 19, 2025, https://www.dailymirror.lk/print/business-main/Morison-opens-largest-pharma-manufacturing-facility-in-Sri-Lanka/245-197119
44. Morison commences commercial production at State-of-the-Art new pharmaceutical manufacturing facility - The Island.lk, accessed May 19, 2025, https://island.lk/morison-commences-commercial-production-at-state-of-the-art-new-pharmaceutical-manufacturing-facility/
45. “QUALITY IS NON-NEGOTIABLE IN PHARMACEUTICALS.” - Morison Limited, accessed May 19, 2025, https://www.morison.lk/wp-content/uploads/2022/06/Logistics-Times-2022-Interview-with-Mr.-Dinesh-Athapaththu.pdf
46. Morison gearing to re-shape pharmaceutical industry in SL by 2030, accessed May 19, 2025, https://www.morison.lk/morison-gearing-to-re-shape-pharmaceutical-industry-in-sl-by-2030/
47. Morison Archives - Lanka Business News, accessed May 19, 2025, https://www.lankabusinessnews.com/tag/morison/
48. Hemas | Home, accessed May 19, 2025, https://www.hemas.com/
49. Performance Review for the Three Months Ended 30th June 2024: Hemas Commits to Sustainable Growth Whilst Navigating Market Challenges, accessed May 19, 2025, https://hemas.com/news/performance-review-for-the-three-months-ended-30th-June-2024.html
50. Investor Presentation- Q4 FY23/24 - Hemas Holdings PLC, accessed May 19, 2025, https://hemas.com/assets/downloads/investor-presentations/investor-presentations-2023-2024-q4.pdf
51. Investor Presentation- Q2 FY24/25 - Hemas Holdings PLC, accessed May 19, 2025, https://hemas.com/assets/downloads/investor-presentations/investor-presentations-2024-2025-q2.pdf
52. Investor Presentation – Q3 FY23 - Hemas, accessed May 19, 2025, https://hemas.com/assets/downloads/investor-presentations/investor-presentations-2022-2023-q3.pdf
53. Leading with Purpose - Hemas, accessed May 19, 2025, https://hemas.com/sustainability.html
54. Hemas Holdings PLC Investor Presentation - Q1 FY 2017–2018, accessed May 19, 2025, https://hemas.com/assets/downloads/investor-presentations/investor-presentati

ons-2017-2018-q1.pdf
55. Hemas Holdings PLC (HHL) - 3Q FY25 - BUY - Strategic Research Limited, accessed May 19, 2025, https://research.bartleetreligare.com/reports/hemas-holdings-plc-hhl-3q-fy25-buy-1044
56. HEMAS HOLDINGS PLC [HHL.N0000], accessed May 19, 2025, https://firstcapital.lk/wp-content/uploads/2024/11/HHL-Earnings-Update-MAINTAIN-BUY-25-11-24.pdf
57. HEMAS HOLDINGS PLC [HHL.N0000], accessed May 19, 2025, https://firstcapital.lk/wp-content/uploads/2024/08/HHL-Earnings-Update-MAINTAIN-BUY-20-08-24.pdf
58. Hemas Holdings (COSE:HHL.N0000) Stock Forecast & Analyst Predictions - Simply Wall St, accessed May 19, 2025, https://simplywall.st/stocks/lk/capital-goods/cose-hhl.n0000/hemas-holdings-shares/future
59. Hemas Holdings PLC - HHL.N0000 - Stock Price & Analysis | Finbox, accessed May 19, 2025, https://finbox.com/COSE:HHL.N0000/
60. Hemas Holdings (COSE:HHL.N0000) - Stock Price, News & Analysis - Simply Wall St, accessed May 19, 2025, https://simplywall.st/stocks/lk/capital-goods/cose-hhl.n0000/hemas-holdings-shares
61. CSELK:HHL.N0000 - hemas holdings plc - TradingView, accessed May 19, 2025, https://www.tradingview.com/symbols/CSELK-HHL.N0000/
62. Financial Year 2023/24 – Twelve Months Performance - Hemas | News, accessed May 19, 2025, https://hemas.com/news/financial-year-2023-24-twelve-months-performance.html
63. Chief Executive Officer's Review: Financial Year 2023/24 First Three Months Performance - Hemas | News, accessed May 19, 2025, https://hemas.com/news/CEO-Review-Q1-2023-24-Hemas-Holdings-PLC.html
64. Hemas revenue grows by 6.7% - The Morning, accessed May 19, 2025, https://www.themorning.lk/articles/I7eFE7PINqipUoXd6Kiy
65. Hemas achieves record earnings for FY 24 - The Island.lk, accessed May 19, 2025, https://island.lk/hemas-achieves-record-earnings-for-fy-24/
66. Hemas Achieves Record Earnings for FY 24 - LankaTalks, accessed May 19, 2025, https://lankatalks.com/post/hemas-achieves-record-earnings-for-fy-24
67. Hemas Holdings reports revenue growth of 10.3-pct in 2023/24 first nine months performance - Lanka Business Online, accessed May 19, 2025, https://www.lankabusinessonline.com/hemas-holdings-reports-revenue-growth-of-10-3-pct-in-2023-24-first-nine-months-performance/